Study Group: Users of In-Situ Hybridization (ISH) in the U.S.(?)

Diagnostic uncertainty in metastatic cancer as to the site of origin remains a problem in medicine today, albeit a slowly shrinking one. Immunohistochemistry using monoclonal antibodies from a host of makers will remain the mainstay in defining the site of origin, but it's proper use depends on accurate...

Integrating conventional blood analysis with flow cytometry paves the way for penetration from the former routine testing market into the latter, specialized cancer testing market.  This platform has the potential to broaden penetration by offering more test capabilities onto an existing platform....

The holy grail of pharmacology is specificity, inventing drugs that faithfully reach their target but do not affect other cells.  Monoclonal antibodies have potential but have not yet reached that mark.  Monoclonal T cell receptors (mTCR) might succeed where all other drugs have failed.

Although many new tests attempt to improve upon current methods of cancer diagnosis, few actually hit that mark.  Typically, they take a benchmark and try to replicate it in terms of efficacy.  This method, however, has the potential to become standard of care for cervical carcinoma screening....

Delay in diagnosis due to an inability to obtain sufficient diagnostic material from the first procedure attempted costs patients, hospitals and insurers, as progressively more invasive (and expensive) modalities are undertaken to determine the nature of a lesion. This randomized trial verifying the...